Targeting gasdermin D to treat myelodysplastic syndromes in people with bone marrow inflammation

Who could benefit from this research

What this research studies

This project uses mouse models that imitate human MDS to study how gasdermin D drives inflammation in the bone marrow. Researchers will test whether inhibiting gasdermin D can reduce the inflammatory signals and slow disease progression. The work focuses on translating findings toward new immunotherapies that could benefit patients with MDS as they age. Results could point to new treatment options that specifically address the inflammatory environment in the bone marrow.

Why it matters

Where this research is happening

• Northwestern University
  Chicago, United States Active

Researchers

• Principal investigator: Ji, Peng — Northwestern University
• Study coordinator: Ji, Peng

Related research

Other NIH-funded projects on the same topics.

• Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant

  This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11453101

• Whole-genome sequencing to refine risk in myelodysplastic syndromes (MDS) for older adults

  This project uses clinical whole-genome sequencing to improve genetic profiling and better predict how MDS will progress in older patients.

  NIH research Washington University · Saint Louis, United States · NIH-11415218

• Understanding why some MDS patients relapse after a stem cell transplant

  A study of patients with myelodysplastic syndromes after stem cell transplant to learn the cellular changes and gene activity that lead to relapse, with the goal of guiding future treatments.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11350441

• Risk factors and inflammation biomarkers for cardiovascular disease in older adults with myelodysplastic syndromes

  A study focuses on older adults with myelodysplastic syndromes to understand why they have higher cardiovascular risk and how inflammatory proteins in the blood might help predict it.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11335686

• Therapeutic targeting of transcription-epigenetic defects in SF3B1-mutant MDS

  A training-focused grant to help a clinician-scientist develop therapies for adults with a common bone marrow failure condition called SF3B1-mutant myelodysplastic syndrome (MDS).

  NIH research Yale University · New Haven, United States · NIH-11332844

• PARP1 and targeted treatment for myelodysplastic syndromes

  This work tests whether blocking a protein called PARP1 can help people with myelodysplastic syndromes who have certain RNA splicing gene mutations.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11325793

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.